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Abstract
Clustered regularly interspaced short palindromic repeats (CRISPR) are composed of numerous repeat-spacer units and are considered a
prokaryotic defence system against foreign nucleic acids. Since antibiotic-resistant genes are frequently encoded in foreign nucleic acids, the
aim of this study was to test whether erythromycin susceptibility in group A streptococcus (Streptococcus pyogenes) is associated with
characteristics of CRISPR elements. Erythromycin susceptibility of 330 isolates collected between 1997 and 2003 was analysed. Among 29
emm types, emm12, emm75 and emm92 showed signiﬁcant changes in erythromycin-resistance rates. By sequencing the spacers from two
CRISPR loci, spacer contents in emm12, emm75 and emm92 strains were associated with erythromycin susceptibility. Strains with fewer
spacers were more resistant to erythromycin. Moreover, in emm4 strains, which showed no signiﬁcant change in their annual
erythromycin-resistance rate, CRISPR type and number of spacers were not correlated with erythromycin susceptibility. These results
highlight a novel association between CRISPR spacer content and erythromycin susceptibility in group A streptococcus.
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Introduction
Clustered regularly interspaced short palindromic repeats
(CRISPR) are a defence system to protect prokaryotes from
phages and conjugative plasmids [1]. CRISPR are composed of
serial repeats, and each repeat is separated by one spacer. Most
spacer sequences are c.30 nucleotides, and some spacers are
identical to the partial sequence of foreign nucleic acids. When
prokaryotes are invaded by foreign nucleic acid, the host can
incorporate small fragments of invading sequence (proto-spac-
ers) into the leader-proximal end of CRISPR to become new
spacers [2]. CRISPR elements can be transcribed into long RNAs
and processed into mature small RNAs, which contain one
spacer and a partial repeat. Mature small RNA, together with
CRISPR-associated (Cas) proteins, can recognize and degrade
the invading sequence in a sequence-speciﬁcmanner. Therefore,
CRISPR provide adaptive immunity against foreign nucleic acids.
Group A streptococcus (GAS, Streptococcus pyogenes) is a
major human pathogen that causes diverse diseases, ranging
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from mild infections to life-threatening diseases [3]. Erythro-
mycin is the alternative choice for the treatment of GAS
infection in penicillin-hypersensitive patients [4,5]. However,
erythromycin-resistant GAS is frequently reported worldwide
[6,7]. ermB, ermA and mefA are the major erythromycin-resis-
tant genes in GAS, and they are frequently encoded in foreign
DNA elements, including transposons, prophages and plasmids
[8–14]. The prevalence of erythromycin resistance is remark-
ably high in Taiwan, with the resistance rate being 40–70%
before 2000 [15,16]. However, after the use of this antibiotic
for acute upper respiratory tract infections was restricted in
February 2001, the erythromycin-resistance rate of GAS
signiﬁcantly decreased to 17% in 2003 [17,18].
There are two CRISPR loci in GAS [19]. Bioinformatic and
genetic studies demonstrated that CRISPR01 could prevent
invasion of foreign DNA into GAS, whereas the role of
CRISPR02 is still controversial [19,20]. Since antibiotic resis-
tance genes are frequently associated with foreign DNA
elements, and CRISPR can prevent infection by foreign nucleic
acids, CRISPR may be associated with antibiotic susceptibility
[21–23]. Therefore, the aim of this study was to determine
whether an association exists between CRISPR and erythro-
mycin susceptibility in GAS.
Materials and Methods
Bacterial characterization
A total of 330 GAS isolates were collected at National Cheng
Kung University Hospital in southern Taiwan during 1997–
2003. Strain characterization, including identiﬁcation, emm
typing, pulsed-ﬁeld gel electrophoresis, antibiotic susceptibility
and erythromycin-resistant gene detection, was carried out as
in previous studies [9,17,24]. The detailed information on
emm4, emm12, emm75 and emm92 strains is listed in the
Supplementary material (Table S1).
Detection of the CRISPR and cas genes
cas genes of CRISPR01 and CRISPR02 loci were detected by
PCR. The primers were designed using the conservation of cas
genes in 17 GAS genome sequences. Among them, 13 strains
had cas genes in CRISPR01 and nine strains had cas genes in
CRISPR02 loci (see Supplementary material, Table S2). The
primers of cas genes were determined by CLUSTALW multiple
alignment (http://www.ebi.ac.uk/Tools/msa/clustalw2/). The
architecture of cas genes and primer binding sites is shown
in Fig. 1. Primer sequences and amplicon sizes are listed in
Table 1.
The primers for CRISPR were designed from the ﬂanking
genes of CRISPR in 17 GAS genome sequences. Among them,
11 and nine strains had CRISPR in CRISPR01 and CRISPR02
loci, respectively (Table S2). The genes csn2 and lepA were
conserved ﬂanking genes of CRISPR01, whereas cas2 and ccdA
genes were the conserved ﬂanking genes of CRISPR02 (Fig. 1).
These genes were analysed by CLUSTALW multiple alignment.
The CRISPR01 was ampliﬁed by primers CRISRP1-3 and
CRISPR1-4 (Table 1) with ExTaq (TAKARA Bio Inc, Shiga,
Japan). Initial denaturation was at 94°C for 5 min, followed by
30 cycles at 94°C for 30 s, annealing at 55°C for 30 s and
elongation at 72°C for 2.5 min. Final elongation was per-
FIG. 1. Two clustered regularly
interspaced short palindromic repeat
(CRISPR) -cas systems in group A
streptococci. This map is drawn based on
emm12 MGAS9429 (accession number
CP000259). White arrows are cas genes.
Grey boxes with vertical grey lines indicate
the repeat-spacer structures of CRISPR.
Light grey arrows are conserved ﬂanking
genes of the CRISPR-cas system. Black
arrows and dark grey arrows are
nucleoside diphosphate kinase genes and
transposons, respectively, which are
diverse among different sequenced strains.
Arrow lines indicate the amplicon of each
primer pair, whose primer sequence and
product size are listed in Table 1.
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formed at 72°C for 10 min. The CRISPR02 was ampliﬁed by
primers CRISPR2-1 and CRISPR2-2 (Table 1) with ExTaq.
Initial denaturation was at 94°C for 5 min, followed by 30
cycles at 94°C for 30 s, annealing at 55°C for 30 s and
elongation at 72°C for 1 min. Final elongation was performed
at 72°C for 10 min. PCR products of CRISPR01 and CRISPR02
were then sequenced at MISSION BIOTECH (Taipei, Taiwan)
using primers CRISPR1-1 and CRISPR2-1 (Table 1), respec-
tively. The Applied Biosystems 3730 DNA Analyzer (Life
Technologies, Carlsbad, CA, USA) was used for sequencing.
Bioinformatic analysis
The spacer and repeat sequences of CRISPR were determined
with CRISPRdb (http://crispr.u-psud.fr/crispr/) [25]. In CRISP-
Rdb, the CRISPRtionary tool was used for spacer identiﬁca-
tion, and conﬁrmed by the CRISPR ﬁnder tool. Locations of
proto-spacers were analysed by ‘Somewhat similar sequences
(blastn)’ in nucleotide BLAST with default parameters (http://
blast.ncbi.nlm.nih.gov/). The results were checked as to
whether these proto-spacers were located in plasmid, phage
or prophage of streptococcus by GenBank, and locations in
prophage were further conﬁrmed by PHAST analysis [26].
Statistical analysis
To evaluate the change of annual erythromycin resistance rate
and the correlation between the number of spacers and
erythromycin MIC, Pearson and Spearman’s correlations were
used. To estimate the correlation between erythromycin
resistance and CRISPR type, the strains with the indicated
CRISPR type were grouped into ‘indicated CRISPR type’
strains. The other strains, which did not harbour the indicated
CRISPR type, were deﬁned as the ‘non-indicated CRISPR type’
strains. Fisher’s exact test was used to estimate the frequency
distribution of erythromycin susceptibility between ‘indicated
CRISPR type’ and ‘non-indicated CRISPR type’ strains. To
compare the number of spacers between erythromycin-resis-
tant and -sensitive strains, the Mann–Whitney U-test or
one-sample t-test was used to estimate the statistical differ-
ence. A p value <0.05 was considered as statistical signiﬁcance.
All of the statistical analyses were calculated in PRISM, version 5
(GraphPad software, San Diego, CA, USA) and SPSS software,
version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
Analysis of the emm types and changes of erythromycin
susceptibility
Among 330 non-repetitive GAS isolates, there were 123
(37.3%) erythromycin-resistant strains (Table 2). The eryth-
romycin-resistance rate was signiﬁcantly decreased from
60.0% in 1997 to 7.1% in 2003 (Table 2, r = 0.95, p 0.001).
A total of 29 emm types were found. Because 18 emm types
were either totally resistant or susceptible to erythromycin
(Table 2), we cannot compare the CRISPR between erythro-
mycin-resistant and erythromycin-sensitive strains within
those 18 emm types. Therefore, they were excluded from
further study.
The other 11 emm types were examined to determine if a
signiﬁcant change in the annual erythromycin-resistance rate
between 1997 and 2003 occurred. The emm12, emm75 and
emm92 strains showed statistically signiﬁcant changes in
erythromycin-resistance rates (r = 0.89, r = 0.81,
r = 0.84, p 0.007, p 0.027 and p 0.018, respectively). These
three emm types were referred to as ‘changing populations’.
The annual erythromycin-resistance rates of the remaining
eight emm types showed no signiﬁcant alterations. Therefore,
they were referred to as ‘stable populations’.
Association of spacer contents and erythromycin
susceptibility in changing populations
There were 66 emm12, 18 emm75 and six emm92 strains.
When we combined all spacers from two CRISPR loci in the 66




size (bp)Designation Sequence (5′ to 3′)
CRISPR01 locus
CRISPR01 CRISPR1-3 cggtacaattcttgtgctcgaa Variablea
CRISPR1-4 tcaatggcgtttaacttgatgg
CRISPR1-1b tgagaaacccgaagtgaa




cas1 C1-cas1-1 tggacgacgattattgct 539
C1-cas1-2 ggaactcctttcccttca
cas2 and csn2 C1-cas2-1 ggctgagggagcataatc 430
C1-csn2-2 tcacttcgggtttctcatt
CRISPR02 locus
CRISPR02 CRISPR2-1 tctgtgacacccgcagaattt Variablea
CRISPR2-2 aaaccagccccgtaacctaaa






cas5 C2-cas5-1 ggttccgactagacaggc 435
C2-cas5-2 ggataggcaaaggaatgg
csd1 C2-csd1-1 ttggctatgaaacttccg 585
C2-csd1-2 acaatggactgtggcatc
csd2 C2-csd2-1 atggtttgatgttcgtgc 360
C2-csd2-2 actcgcatagagccttcc
cas4 C2-cas4-1 gataatgaagcgacagcg 505
C2-cas4-2 tcaacctgggcttacaaa
cas1 C2-cas1-1 atgggaatgtgttgttgc 648
C2-cas1-2 tatgcttacgcttctgcc
cas2 C2-cas2-1 aaatacggaaacacctgct 240
C2-cas2-2 tcatagctgtctgagcgac
aProduct size is dependent on the number of the repeat-spacer units.
bThis primer was used for sequence of the PCR products generated by CRISPR1-3
and CRISPR1-4.
cA positive signal from at least one primer pair was deﬁned as the presence of the
cas9 or cas3 gene.
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emm12 strains, nine different combinations were found, which
were designated as CRISPR types 1–9 (Table 3). When
compared with other ‘non-indicated CRISPR type’ strains,
strains with CRISPR types 5 and 7 were more likely to associate
with erythromycin susceptibility (Table 3, p 0.018 and p 0.008,
respectively). Strains with CRISPR types 2 and 6 were more
likely to be erythromycin-resistant (Table 3, p <0.001 and
p 0.03, respectively). ermB-containing and mefA-containing
strains were more likely to be CRISPR types 2 and 6,
respectively (Table 3, p <0.001 and p <0.001, respectively).
Among 18 emm75 strains, 14 and four strains belonged to
subtype emm75.0 and emm75.1, respectively. The difference
between emm75.0 and emm75.1 was only one nucleotide
difference (see Supplementary material, Fig. S1). Two CRISPR
types were identiﬁed, which were designated as CRISPR types
10 and 11 (Table 4). Fourteen erythromycin-resistant
emm75.0 strains (mefA+) had CRISPR type 10. Four erythro-
mycin-susceptible emm75.1 strains had CRISPR type 11
(Table 4). Erythromycin susceptibility was signiﬁcantly associ-
ated with two CRISPR types (Table 4, p <0.05).
Amongsixemm92strains, threeCRISPR typeswere identiﬁed,
which were designated as CRISPR types 12–14 (Table 4). Three
erythromycin-resistant strains (mefA+) had CRISPR type 12, and
the other three erythromycin-susceptible strains had CRISPR
types 13 and 14 (Table 4). Based on pulsed-ﬁeld gel electropho-
resis typing, these strains were not the same (Table S1).
Fewer spacers in erythromycin-resistant strains
All of the emm12 and emm92 strains had two CRISPR loci; the
number of spacers in one strain was calculated by adding the
TABLE 2. Distribution of erythromycin-susceptible and erythromycin-resistant group A streptococci from 1997 to 2003
emm type
No. of erythromycin-resistant strains/No. of total strains
1997 1998 1999 2000 2001 2002 2003 Total
All resistant or susceptible to erythromycina
9/10 3/5 2/11 1/7 0/3 1/13 1/23 17/72
Changing population
12 3/5 3/6 5/10 10/24 4/8 2/5 1/8 28/66
75b 7/7 6/6 0/1 1/2 0/0 0/2 0/0 14/18
92 0/0 0/0 0/0 0/0 1/2 1/3 1/1 3/6
Stable population
4 11/25 6/7 3/3 4/6 1/2 1/2 0/3 26/48
Othersc 12/23 7/11 8/14 4/12 1/4 1/21 2/35 35/120
Total 42/70 25/35 18/39 20/51 7/19 6/46 5/70 123/330
aemm33, emm58, emm63, emm66, emm80, emm93 and emm103 strains are all resistant to erythromycin. Others are erythromycin-susceptible strains, including emm6, emm49,
emm76, emm78, emm87, emm99, emm101, emm115, emmSp9458/VT8, emmSp11014/VT15 and emmst212 strains.
bSeveral strains harbour different emm subtypes. Four strains of emm75 are emm75.1, and the others are emm75.0.
cThey are emm1, emm11, emm13, emm22, emm82, emm89 and emm106 strains.
TABLE 3. Correlation of clustered regularly interspaced short palindromic repeat (CRISPR) types, erythromycin susceptibility
and erythromycin-resistant genes in emm12 group A streptococci
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number of individual spacers from both CRISPR01 and
CRISPR02 loci. In emm75 strains, as the repeat-spacer
structures of the CRISPR01 locus were not present (Table 4),
the number of spacers in a strain was only calculated from the
CRISPR02 locus.
Sixty-six emm12 strains were divided into three groups,
including ermB-containing (20 strains), mefA-containing (eight
strains), and erythromycin-susceptible (38 strains) groups. The
ermB-containing strains had signiﬁcantly fewer spacers than
mefA-containing and erythromycin-susceptible strains (Fig. 2a,
Mann–Whitney U test, p <0.05). Erythromycin MIC and
number of spacers showed a signiﬁcant negative correlation
(Table 5, r = 0.56, p <0.0001).
To exclude the statistical interference from possible clonal
strains, strains with the same pulsed-ﬁeld gel electrophoresis
type, CRISPR type and erythromycin-resistance gene were
removed. Twenty-four emm12 strains, including six ermB-con-
taining strains, two mefA-containing strains and 16 susceptible
strains remained. A signiﬁcant negative correlation was still
found between erythromycin MIC and the number of spacers
(Table 5, r = 0.42 and p 0.0418). ermB-containing strains
also had signiﬁcantly fewer spacers than susceptible strains
(data not shown).
All erythromycin-resistant and erythromycin-susceptible
emm75 strains had three and six spacers in their CRISPR02
locus, respectively. Erythromycin-resistant emm75 strains had
signiﬁcantly fewer spacers than erythromycin-susceptible
strains (Fig. 2b, Mann–Whitney U test, p <0.01). In emm92
strains, all erythromycin-resistant strains had ten spacers while
the average number of spacers in erythromycin-susceptible
strains was 16.67. Erythromycin-resistant emm92 strains also
had signiﬁcantly fewer spacers than erythromycin-susceptible
strains (Fig. 2c, one-sample t test, p <0.01).
TABLE 4. Distribution of spacer content and erythromycin susceptibility of emm4, emm75 and emm92 strains
U
TABLE 5. Distribution of number of spacers and minimal
inhibitory concentration among emm12 strains
No. of
spacers










MIC  SDa (mg/L)
4 1 0.12  0.00 1 0.12  0.00
5 19 215.59  95.87 6 128.05  140.17
6 23 45.30  98.90 7 75.49  123.45
7 9 7.13  5.03 2 4.03  5.61
8 2 0.12  0.00 2 0.12  0.00
9 12 0.07  0.03 6 0.06  0.04
aSD, standard deviation.
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No correlation between CRISPR and erythromycin
susceptibility in stable populations
Among eight emm types in stable populations, there are 61
erythromycin-resistant strains, including 26 erythromy-
cin-resistant strains in emm4 and 35 erythromycin-resistant
strains from seven other emm types (Table 2). emm4 had the
most erythromycin-resistant strains in a stable population.
Therefore, emm4 strains were chosen for further analysis
to represent the characteristics of CRISPR in stable
populations.
All 48 emm4 strains, including 26 erythromycin-resistant and
22 erythromycin-sensitive strains, only had a CRISPR02
(Table 4). Five different spacer combinations were found, which
were designated asCRISPR types 15–19 (Table 4). Therewas no
signiﬁcant association between CRISPR type and erythromycin
susceptibility (Table 4, p >0.05). The number of spacerswas not
signiﬁcantly different between erythromycin-resistant and
erythromycin-susceptible strains (Fig. 2d, Mann–Whitney U
test, p >0.05).
The presence of cas genes in emm4, emm12, emm75 and
emm92 strains
All emm4, emm12, emm75.0 and emm92 strains contained cas
genes in CRISPR01 and CRISPR02 loci (Table S1, and intact cas
genes of the two CRISPR loci are shown in Fig. 1). However,
four emm75.1 strains, which lacked CRISPR01, were devoid of
CRISPR01 locus-associated cas genes.
Proto-spacers in emm4, emm12, emm75 and emm92 strains
There were 5, 10, 16 and 19 different spacers in emm4,
emm12, emm75 and emm92, respectively (Table 3 and Table 4;
the designation and sequences of each spacer are listed in the
Supplementary material, Table S3). BLASTN analysis showed
that all of the proto-spacers were located in prophage
elements except the proto-spacers C, J and U, which were
found in the core-genome region (see Supplementary material,
Table S4). However, none of the spacers targeted to the
known ermB-, ermA- or mefA-containing foreign elements
(Table S4).
Discussion
We found that when GAS showed a signiﬁcant change of
erythromycin-resistance rates, CRISPR type and number of
spacers were associated with erythromycin susceptibility.
Furthermore, cas genes were present in all the analysed
strains except emm75.1 strains, indicating that deletion of cas
genes was not related to erythromycin resistance in GAS.
Association between CRISPR and antibiotic resistance has
been shown in Streptococcus thermophilus, Erwinia amylovora and
Enterococcus spp. [21,22,27]. In S. thermophilus, the cat-con-
taining plasmid could be recognized and degraded by newly
acquired spacers, and chloramphenicol susceptibility would be
increased [22]. In E. amylovora, most streptomycin-resistant
strains have the same spacers, whereas susceptible strains have
diverse spacer contents [27]. In Enterococcus spp., strains with
an incomplete CRISPR-cas system have signiﬁcantly more
antibiotic-resistance genes than those with a complete
CRISPR-cas system [21,23]. However, the association between
antibiotic resistance and CRISPR in GAS is based on the spacer
arrangement, and deletion of cas genes is not associated with
(a) (b)
(c) (d)FIG. 2. Distribution of number of
spacers in emm12 (a), emm75 (b),
emm92 (c) and emm4 (d) group A
streptococci. The number of spacers in
each strain is represented as closed circles
and a horizontal line indicates the average
number of spacers in each group.
EM indicates erythromycin. * indicates
p <0.05.
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erythromycin resistance. These examples indicate that the
relationship between CRISPR and antibiotic resistance can vary
among different species.
The immunity conferred by CRISPR is known to rely on
sequence complementarity between spacer and target
sequences. All spacers can target foreign elements with the
exception of spacers C, J and U, which can target core genome
regions. Interestingly, similar data are also found in Escherichia
coli UTI89, APECO1 and S88. Several spacers of these strains
can target but not degrade their own plasmids [28]. It is still
unknown how bacteria maintain their genetic integrity under
such conditions. None of the other spacers can target known
erythromycin-resistance elements. Because recombination is
frequently found in foreign elements [29,30], erythromycin-
resistance genes might be recombined to create novel erythro-
mycin-resistant elements, which are not present in the GenBank
database. Therefore, BLASTN may not show direct targeting
between spacers and erythromycin-resistant elements.
In this study, all emm12 strains except one support our
hypothesis. Those with more spacers are more susceptible to
erythromycin, indicating that these strains may have better
immunity against erythromycin-resistant elements [19,28].
However, as one strain with four spacers is sensitive to
erythromycin (among 66 emm12 strains), more strains should
be collected for further analysis. Besides, most associations are
based on the CRISPR02 locus, whose activity is still contro-
versial [19,20]. Therefore the mechanisms resulting in the
association between CRISPR type, number of spacers and
erythromycin susceptibility are topics for further studies.
In summary, we found that the arrangement and number of
CRISPR spacers are associated with erythromycin susceptibil-
ity in emm12, emm75 and emm92 strains of group A
streptococcus. Although the underlying mechanisms remain
to be studied further, our data suggest that analysis of CRISPR
elements can be useful in evolutionary and epidemiological
studies of antibiotic resistance.
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